Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer
Advanced Gastric Cancer
Conditions: official terms
Stomach Neoplasms
Conditions: Keywords
intraperitoneal chemotherapy, cisplatin, fluorouracil, advanced gastric cancer
Study Type
Study Phase
Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Name: cisplatin, Fluorouracil
Type: Drug
Overall Status
Gastric cancer is the leading cause of death from a intestinal tract cancer in China.In most cases, the high death rate is due to tumor that has spread beyond the gastric cancer at the time of diagnosis. In China, the standard chemotherapy for the initial treatment of gastric cancer is a combination of a platinum analogue with 5-Fu.With modern surgical interventions and contemporary chemotherapy, most patients attain better clinical remission.The majority of them, however, will eventually have a relapse and die of the disease.

The peritoneal cavity is the principal site of disease in gastric cancer.Although the intensity of intravenous chemotherapy is limited mainly by myelotoxicity, several active drugs can be administered directly into the peritoneal cavity. The rationale for intraperitoneal therapy in gastric cancer is that the peritoneum, the predominant site of tumor, receives sustained exposure to high concentrations of antitumor agents while normal tissues, such as the bone marrow, are relatively spared.

The investigators conducted this trial to investigate the efficacy and safety of intraperitoneal chemotherapy in advanced gastric cancer.
Detailed Description
To investigate efficacy and safety of intraperitoneal chemotherapy as part of adjuvant treatment for advanced gastric cancer.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:


- Histologically confirmed primary adenocarcinoma of the stomach

- 3-4weeks after radical operation for gastric cancer

- Stage of the gastric cancer was T3-4NxM0


- Age: 18 - 70years old

Life expectancy:

- Longer than 3 months


- Granulocyte count at least 1,500/mm3

- Platelet count at least 100,000/mm3

- Hemoglobin at least 80*10^12/mm3


- AST no greater than 2.5 times ULN


- Creatinine no greater than 1.5 times ULN


- Fertile patients must use effective contraception


Biologic therapy:

- Not specified


- Prior chemotherapy and radiotherapy were not allowed

- No other concurrent chemotherapy


- Locally radiotherapy for local disease of advanced gastric cancer during adjuvant treatment was allowed


- See Disease Characteristics

- Prior surgery for gastric cancer was necessary

Exclusion Criteria:

- Haven't recovery from operation or complication of operation

- With the following risk factors: Uncontrolled or severe cardiovascular disease (e.g., myocardial infarction within the past 6 months, congestive heart failure treated with medications, or uncontrolled hypertension)

- Pregnant or nursing

- Other currently active malignancy except nonmelanoma skin cancer

- Uncontrolled or severe bleeding,diarrhea,intestinal obstruction,adhesion of intestine

- metastasis before enrollment

- Received other chemotherapy or radiotherapy after operation
Fudan University Cancer Hospital
Shanghai, Shanghai, China
Status: Recruiting
Contact: Jin Li, MD - 86(021)64175590 - fudanlijin@163.com
Start Date
August 2009
Completion Date
December 2011
Fudan University
Fudan University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page